Arog’s Phase III trial of crenolanib met its primary endpoint and improved OS and EFS in patients with NPM1/FLT3 co‑mutated ...

CLN-049’s anti-leukaemic impact was observed regardless of FLT3 status, which is the most commonly mutated protein in AML.

Among fit patients with acute myeloid leukemia, the combination of azacitidine plus Venclexta (venetoclax) was associated ...

Patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML) had a high response rate and prolonged event-free survival (EFS) following treatment with an investigational FLT3 inhibitor and ...

CLN-049 monotherapy demonstrates promising efficacy, including multiple complete responses and encouraging response durability, in a heavily ...

NPM1 minimal residual disease (MRD) positivity before allogeneic hematopoietic cell transplantation is linked to higher relapse rates and lower overall survival in patients with acute myeloid leukemia ...

RNA interference (RNAi) offers a promising approach for AML patients with FLT3-ITD mutations, addressing challenges like drug resistance and high relapse rates. Lipopolymers have demonstrated efficacy ...

HOUSTON -- Post-transplant maintenance with an FLT3 inhibitor significantly improved overall survival (OS) in FLT3-positive acute myeloid leukemia (AML), according to a subgroup analysis of a ...

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, ...

The illustration of protein structure (domains) on the left side, and corresponding exons in the FLT3 gene are displayed on the right side. FMS-like tyrosine kinase 3 (FLT3) mutations represent some ...

Guidelines recommend older adults with newly diagnosed AML should be offered antileukemic therapy over best supportive care.

CLN-049, a novel FLT3/CD3 bispecific T-cell engager, has received fast track designation from the FDA for the treatment of relapsed or refractory (R/R) acute myeloid leukemia (AML). 1 ...